Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
A new study by Sandra Amaral and her team has found that children with chronic kidney disease (CKD), regardless of disease severity,...
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]
Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.
Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome
1.
Papillary thyroid cancer: New markers offer hope for tailored treatment
2.
To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.
3.
Is a $2,000 Whole-Body MRI Worth It?
4.
Housing aid linked to lower medical financial hardship among US renters with cancer
5.
Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC
1.
Hepatocellular Carcinoma: Progress in Detection, Pathogenesis, and Treatment
2.
Understanding Cold Agglutinin Disease: Symptoms, Diagnosis, and Treatment Options
3.
Examining Serum Osmolality: What It Is And How To Test For It
4.
A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures
5.
Introduction To Immune Thrombocytopenic Purpura
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Navigating the Complexities of Ph Negative ALL - Part XI
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge